Canada Approves Public Reimbursement for Early Alzheimer’s Drug Leqembi

Canada’s national drug agency has issued a final positive recommendation supporting public funding for lecanemab, a treatment for early-stage Alzheimer’s disease.

31 Aug, 23:30 — 31 Aug, 23:30

Post Share

Sources

Showing 1 of 1 sources

taiwan-newsMostly Factual3d ago

Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease - Taiwan News

Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease Taiwan News

Read full article →

Canada Approves Public Reimbursement for Early Alzheimer’s Drug Leqembi

Sources

Canada’s Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement of LEQEMBI® (lecanemab) for Early Alzheimer’s Disease - Taiwan News

Related Stories

UNICEF Report Finds 20 Million Children Annually Face Online Sexual Exploitation

Genetically Modified Pig Kidney Keeps US Patient Alive for Record Nine Months

Pentagon Temporarily Rescinds Testosterone Screening Guidance for Troops

RFK Jr. Allegedly Requested Removal of Measles Deaths From CDC Tally